Congestive Heart Failure: Worldwide Drug and Medical Device Markets - PDF

Please download to get full document.

View again

of 8
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Information Report
Category:

Essays & Theses

Published:

Views: 2 | Pages: 8

Extension: PDF | Download: 0

Share
Related documents
Description
Brochure More information from Congestive Heart Failure: Worldwide Drug and Medical Device Markets Description: Approximately 23 million people worldwide
Transcript
Brochure More information from Congestive Heart Failure: Worldwide Drug and Medical Device Markets Description: Approximately 23 million people worldwide are afflicted with congestive heart failure (CHF), and 2 million new cases of CHF are diagnosed each year worldwide. In contrast to other cardiovascular disorders that have actually declined during the past few decades, the incidence of heart failure is on the rise. It is, in fact, the most rapidly growing cardiovascular disorder in the United States. There is no cure for CHF short of a heart transplant. Although advances in pharmacology have led to better treatment, 50% of the patients with the most advanced stage of heart failure die within a year. Typically, heart failure patients receive several chronic oral therapies, including diuretics, ACE inhibitors, beta-blockers and inotropic agents. However, a new class of CHF drugs created by biotechnology companies will soon be on the market. These new drugs will lead the way to a revolution in the treatment of CHF and could spark a biotechnology boom similar to the AIDS breakthroughs of 1996 and A majority of patients are treated with drug therapy, but for patients with advanced CHF, device-based therapy or transplantation are their only alternatives. A large number of patients with advanced CHF have received left ventricular assist devices, and a number of promising technologies, including biventricular pacing and defibrillators, ventricular remodeling, and ventricular assist devices represent exciting, growing markets. Kalorama s Congestive Heart Failure: Worldwide Drug and Medical Device Markets thoroughly reviews the current state of the markets in this expanding field, including developments in drug therapy and technological advances in the device markets. Contents: Chapter One: Executive Summary Background Scope and Methodology Size and Growth of Market Market Trends The Nature of the Industry The New Technologies - Pharmaceutical - Medical Device Chapter Two: Overview of Congestive Heart Failure Background Pathophysiology - Types of Heart Failure - Theories of Congestive Heart Failure Conditions Leading to Congestive Heart Failure - Myocardial Infarction - Hypertension - Cardiomyopathy - Atrial Fibrillation - Other Risk Factors Diagnosis of Congestive Heart Failure Classification of Patients Epidemiology - United States - Europe - Japan Chapter Three: Treatment of Congestive Heart Failure Pharmacologic Therapy - Overview - Standard Pharmacologic Therapy - The Market for CHF Pharmaceuticals - Leading Products - Leading Competitors Congestive Heart Failure Devices - Overview - Bridge to Transplant - Extended Use - ACC Guidelines - Intervention Device Products - The Market for Intervention Devices - Leading Products - Leading Competitors Chapter Four: Congestive Heart Failure Patient Management Guidelines for Management of Chronic Heart Failure Strategies to Maintain Quality Patient Care and Contain Costs - Patient Education Programs - Dedicated Multidisciplinary Congestive Heart Failure Clinics Chapter Five: Emerging Technologies To Treat Congestive Heart Failure Pharmacologic Treatments Medical Devices Biotechnology Chapter Six: Company Profiles Abiomed, Inc. Acorn Cardiovascular, Inc. Actelion Ltd. Arrow International Bioheart, Inc. CardioEnergetics, Inc. CV Therapeutics GenVec, Inc. Geron Corporation Guidant Corporation MediGene AG MedQuest Products, Inc. Medtronic, Inc. MicroMed Technology, Inc. Myocor, Inc. Myogen St. Jude Medical Somanetics Corporation Texas Biotechnology Corporation Thoratec Corporation Chapter Seven: Conclusions and Strategic Implications Prevention Over Treatment Medical Approaches Over Surgical Approaches Accelerating Device Development Device Competition Heats Up Big Pharma Still Dominant Biotech Emerges Transplant Alternatives on the Way Drug Market Outpaces Epidemiology Appendix A: Glossary Appendix B: Company Directory List of Exhibits Chapter One: Executive Summary Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World Healthcare Markets, Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World Healthcare Markets, Figure 1-3: The Total Market for Congestive Heart Failure Therapeutics in the Major World Healthcare Markets: Table 1-1: Estimated Market Sizes for CHF Pharmaceuticals in the Major World Healthcare Markets, Table 1-2: Estimated Market Sizes for CHF Devices in the Major World Healthcare Markets, Figure 1-4: Trending in the World s Major Congestive Heart Failure Therapy Markets (Total), Figure 1-5: Composition of the Markets for Congestive Heart Failure Therapeutics by Product Classification: Table 1-3: Key Competitors in Congestive Heart Failure Therapeutics Chapter Two: Overview of Congestive Heart Failure Table 2-1: Common Contributors to Congestive Heart Failure Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World s Major Healthcare Markets, Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World Healthcare Markets, Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World Healthcare Markets, Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 1999 Table 2-2: Incidence and Prevalence of CHF in the United States: Figure 2-5: Incidence and Prevalence of CHF in the United States: Figure 2-6: Prevalence of Congestive Heart Failure in the United States by Age and Sex: Figure 2-7: The Distribution of Congestive Heart Failure Among the Five Major European Healthcare Markets, 2002 Table 2-3: Incidence and Prevalence of CHF in the Major European Healthcare Markets, Figure 2-8: Incidence and Prevalence of CHF in the Major European Healthcare Markets, Table 2-4: Incidence and Prevalence of CHF in the Japanese Healthcare Market, Figure 2-9: Incidence and Prevalence of CHF in the Japanese Healthcare Market, Chapter Three: Management of Congestive Heart Failure Table 3-1: Therapeutic Strategies for Symptomatic Congestive Heart Failure Table 3-2: Pharmacologic Response to the Pathophysiology of Cardiac Performance Table 3-3: Common ACE Inhibitors Available for the Treatment of CHF Table 3-4: Common Angiotensin II Receptor Antagonists Available for the Treatment of CHF Table 3-5: Common â-receptor Antagonists Available for the Treatment of CHF Table 3-6: Common Diuretics Available for the Treatment of CHF Table 3-7: Common Inotropic Drugs Available for the Treatment of CHF Table 3-8: Common Vasodilators Available for the Treatment of CHF Table 3-9: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, Figure 3-1: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, Figure 3-2: Distribution of the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major World Healthcare Markets, Table 3-10: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the United States, Figure 3-3: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the United States, Figure 3-4: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the United States, Table 3-11: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major European Markets: Figure 3-5: Trending in the Estimated Historic and Forecast Markets for CHF Pharmaceuticals in the Major European Markets, Figure 3-6: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the Major European Markets, Table 3-12: Estimated Historic and Forecast Markets for CHF Pharmaceuticals in Japan, Figure 3-7: Trending in the Estimated Historic and Forecast Markets For CHF Pharmaceuticals in the Major Japanese Markets, Figure 3-8: Distribution of the Estimated Historic and Forecast Market Segments for CHF Pharmaceuticals in the Major Japanese Markets, Table 3-13: Companies Actively Addressing the CHF Pharmaceutical Markets Table 3-14: Key Competitors in the CHF Pharmaceutical Arena Table 3-15: Guidelines for the Choice of Pacemaker Generator In Selected Indications for Pacing Table 3-16: Biventricular Pacemakers for CHF Therapy Table 3-17: Cardioverter/Defibrillators (ICD) Available for Use in the Treatment of CHF Table 3-18: Ventricular Assist Devices (VADs) On the Market and in Development Table 3-19: The Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment Figure 3-9: Trending in the Estimated Markets for Devices to Treat CHF In the Major World Healthcare Markets by Geographic Segment Figure 3-10: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment Table 3-20: Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Geographic Segment Figure 3-11: Trending in the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment Figure 3-12: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment Table 3-21: The Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment Figure 3-13: Trending in the Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment Figure 3-14: Distribution of the Estimated Markets for Devices to Treat CHF in the United States Healthcare Market by Device Segment Table 3-22: The Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets by Device Segment Figure 3-15: Trending in the Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets by Device Segment Figure 3-16: Distribution of the Estimated Markets for Devices to Treat CHF in the Major European Healthcare Markets By Device Segment Table 3-23: The Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment Figure 3-17: Trending in the Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment Figure 3-18: Distribution of the Estimated Markets for Devices to Treat CHF in the Japanese Healthcare Market by Device Segment Chapter Four: Congestive Heart Failure Patient Management Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of Congestive Heart Failure by Stage of the Disease Table 4-1: ACC/AHA Staging of Congestive Heart Failure Table 4-2, 2001 ACC/AHA Guidelines for Evaluation and Treatment for Congestive Heart Failure Chapter Five: Emerging Technologies To Treat CHF Table 5-1: New Drugs in Development for the Treatment of Congestive Heart Failure Table 5-2: Medical Devices in Clinical Trials for the Treatment of Congestive Heart Failure Table 5-3: Biotechnology-Based Therapeutics for Congestive Heart Failure in Development Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Congestive Heart Failure: Worldwide Drug and Medical Device Markets SC Product Formats Please select the product formats and quantity you require: Quantity Hard Copy: Electronic (PDF) - Single User: Electronic (PDF) - Enterprisewide: USD USD 56 Shipping/Handling USD 2625 USD 5250 * Shipping/Handling is only charged once per order. * The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL) Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World
Recommended
View more...
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks